Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02812524 | Ipilimumab for Head and Neck Cancer Patients | PHASE1 | ACTIVE NOT_RECRUITING | 18 | — | — | Nov 18, 2016 | Dec 1, 2026 | Apr 24, 2026 | 1 | United States |
The percentage of patients with surgery delayed possibly related to the study drug.
| Arm | Type | Description |
|---|---|---|
| Intratumoral Ipilimumab | EXPERIMENTAL | Patients receive a 3mg intratumoral injection of ipilimumab during a biopsy procedure. |
| Name | Type | Description |
|---|---|---|
| Intratumoral Ipilimumab | DRUG | Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor. |
Inclusion Criteria: * Patients with SCCHN who are planned for surgical resection and in the opinion of the surgeon are able to safely undergo tissue biopsy plus intratumoral (IT) injection in advance, with special consideration given to risk of occlusion or compression of airway or major vessels in...